BenevolentAI: Uncovering possible COVID-19 treatments

Drug discovery is an immensely challenging problem. Under the traditional model it takes years to develop and test new drugs, evidenced by the impatient wait for a COVID-19 vaccine. Until then, we will rely on repurposing existing drugs to ease symptoms in severely affected patients. Over the last few years, BenevolentAI has amassed a substantial biomedical knowledge graph on AWS - set up to discover and develop new treatments. Given the urgency of the escalating crisis, Benevolent deployed its data, systems and in-house scientific expertise to rapidly uncover a promising treatment option in the form of an existing rheumatoid arthritis drug. This is the story of what they did, and what happened next.

Presented by Olly Oechsle, Lead Applications Engineer, Benevolent.AI

Previous Video

Eli Lilly: Making Research FAIR- Solving the Silos of Data at Lilly Research Labs

Presented by Adam West, Director of Discovery Informatics, Eli Lilly

Next Video

Otsuka: Using Tech to Develop Digital Biomarkers and Improve the Efficiency of Clinical Trials

Presented by Brian Johnson- Director, Applied Innovation & Process Improvement, Otsuka

Questions? Talk to us.

First Name

Last Name

Phone Number

Company Name

Country/Region

State/Province

Postal Code

Industry

Job Role

Job Title

Level of AWS Usage

Company Type

Company Size

I am completing this form in connection with my:

By completing this form, I agree that I'd like to receive information from Amazon Web Services, Inc. and its affiliates (AWS) related to their services, events and any special offers by email, post, or other forms of communication.

You may unsubscribe at any time by following the instructions in the communications received. Your information will be handled in accordance with the AWS Privacy Notice.